Why Europe’s Drug Delivery Future Starts at Home

Home-based care is reshaping Europe’s drug delivery market, driving targeted consolidation, fresh debates on value, and steady investment in patient-friendly systems

19 Dec 2025

Europe’s drug delivery sector is gaining prominence as patient expectations, cost pressures and selective consolidation reshape a market long treated as a supporting function within pharmaceuticals.

The change is driven largely by how care is delivered. A growing number of European patients with chronic conditions now manage treatment at home and expect medicines that fit easily into daily routines. This has increased demand for delivery formats such as auto-injectors, prefilled syringes and improved inhaler technologies, which are designed to be simpler to use and reduce the burden on patients.

Health systems are reinforcing the shift. Workforce shortages and tight budgets are pushing providers to encourage home-based care where clinically appropriate, reducing reliance on hospitals and outpatient clinics. Drug delivery devices that support self-administration and adherence therefore align with broader policy goals.

Market data suggest steady, if uneven, growth. Europe accounts for a sizeable share of the global drug delivery market, which analysts expect to expand at a mid-single-digit annual rate through the end of the decade. Segments linked to ease of use and adherence are widely seen as growing faster than more traditional formats.

Companies are adjusting their strategies. Some device makers and packaging groups have pursued targeted acquisitions in Europe to add design expertise, manufacturing capacity or regulatory capabilities. Rather than broad consolidation, these deals reflect efforts to meet pharmaceutical companies’ demand for more integrated and reliable delivery solutions.

Expectations from drug manufacturers are also changing. Delivery systems are increasingly assessed not only on cost but on usability, reliability and evidence that they support better adherence. Partnerships or acquisitions can shorten development timelines and reduce risk, particularly as regulatory standards become more demanding.

Pricing remains contentious. European payers continue to focus on upfront costs, even as manufacturers argue that better delivery systems can reduce hospital visits and improve long-term outcomes. This has fuelled debate over how to capture broader value, rather than assessing innovation solely through purchase price.

Regulation adds further complexity. Higher requirements for safety, usability testing and supply security raise development costs, favouring groups with scale and established quality systems.

Despite these challenges, sentiment remains cautiously positive. Patient demand for convenient therapies is clear, health systems broadly support care outside hospitals, and investment in delivery innovation continues. As targeted consolidation and collaboration progress, drug delivery is set to play a larger role in how medicines are developed and used across Europe.